OSL oncosil medical ltd

This thread is for talking about the medical side of things and...

  1. 6,553 Posts.
    lightbulb Created with Sketch. 252

    This thread is for talking about the medical side of things and patient benefits --
    . I used Medical Doctor GPT of Chat GPT - AI research as usual. - I can highly recommend it for all other medical queries you may have. - In this context however, as always, do your own research and ask your fin. advisor.
    .Medical Doctor GPT of Chat GPT - AI research: -->
    The results in the image highlight the potential benefits of integrating OncoSil™ into the treatment plan for patients with unresectable locally advanced pancreatic cancer (LAPC). Here's a deeper look into the study outcomes and their implications:
    https://hotcopper.com.au/data/attachments/6564/6564479-181312d789d971435456be6c4436edad.jpg

    1. Surgical Resection Rates:

    • The study shows that around 1 in 4 patients (28.6%) treated with the combination of OncoSil™ + chemotherapy achieved surgical resection with curative intent.
    • In comparison, only 12.1% of patients receiving chemotherapy alone were able to undergo surgery.
    • This difference suggests that OncoSil™ may play a significant role in making previously unresectable tumors operable, potentially leading to improved overall survival and disease-free survival.
    • Surgical resection is generally regarded as the only potential cure for pancreatic cancer, so doubling the resection rate is a crucial achievement.

    2. Tumor Downstaging:

    • Tumor downstaging refers to reducing the tumor size sufficiently to make surgery feasible, even if the patient was not initially eligible for resection.
    • Nearly 1 in 3 patients (31.4%) receiving OncoSil™ + chemotherapy experienced successful downstaging, compared to 13.6% with chemotherapy alone.
    • This improvement emphasizes the ability of OncoSil™ to work synergistically with chemotherapy, making the cancer more manageable and opening up potential avenues for further treatment.

    3. Survival Outcomes in Resected Patients:

    • Among the patients who underwent surgery, 6 out of 10 (60%) were alive at a median follow-up of 32 months.
    • Importantly, 5 of these 6 patients (50%) showed no evidence of disease (NED), indicating a strong possibility of prolonged disease control or remission.
    • This long-term survival benefit highlights the potential of OncoSil™ to not only enable surgery but also contribute to durable, improved outcomes for a subset of patients.

    4. Mechanism and Benefits of OncoSil™:

    • OncoSil™ is a localized radioactive isotope implant (phosphorus-32) that delivers high-dose radiation directly to the tumor. This approach may help shrink the tumor more effectively than systemic therapy alone, as it minimizes radiation exposure to surrounding healthy tissues.
    • The direct tumor-targeting mechanism of OncoSil™ appears to be a major factor in enhancing resectability and downstaging rates, working alongside chemotherapy to weaken the tumor further.
    • OncoSil™ is designed to be minimally invasive and is typically delivered through endoscopic ultrasound (EUS)-guided injection, offering a relatively low-risk, targeted treatment option for LAPC.

    5. Implications for Clinical Practice:

    • These findings suggest that OncoSil™ may be considered as an addition to the standard-of-care chemotherapy regimen for patients with unresectable LAPC, especially those with borderline resectable tumors.
    • The study also supports the notion that aggressive multi-modal treatment (local + systemic) can significantly improve resectability and survival chances.
    • However, further studies, including larger randomized trials, are needed to confirm these results and establish OncoSil™ as a standard adjunct therapy in this patient population.

    Overall, the integration of OncoSil™ into treatment regimens shows promising potential for improving outcomes in an otherwise challenging cancer type, offering hope for more patients to achieve potentially curative surgery.

    ---
    this is all very good news

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.20
Change
0.000(0.00%)
Mkt cap ! $22.58M
Open High Low Value Volume
$1.12 $1.20 $1.12 $9.106K 7.756K

Buyers (Bids)

No. Vol. Price($)
1 7250 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.20 3123 5
View Market Depth
Last trade - 15.02pm 13/08/2025 (20 minute delay) ?
OSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.